Assessment of efficacy of tyrosine kinase inhibitors in treatment of chronic myeloid leukemia
Abstract
This research demonstrated treatment results of 45 patients with chronic myeloid leukemia who were monitored from 2006 to 2015 year. The article is aimed to evaluate a frequency of achievement of hematologic, cytogenetic, molecular responses in patients administered with tyrosine kinase inhibitors. It is shown that the treatment of choice for CML is tyrosine kinase inhibitor – imatinib. The use of tyrosine kinase inhibitors allows to reach deep cytogenetic and molecular remission in patients with chronic myeloid leukemia which leads to increased survival. Autors noted a high prevalence of primary and secondary resistance to first generation tyrosine kinase inhibitor – imatinib. Investigation of results demonstrated that regular hematological, cytogenetic and molecular monitoring are required for effective disease control.
About the Authors
V. N. Yadrikhinskaya
M.K. Ammosov North-Eastern federal university, Institute of medicine
Russian Federation
Russian Federation
Yadrikhinskaya Vera Nikolaevna –candidate for medical sciences
associate professor at the department «Hospital therapy, occupational diseases and clinical pharmacology»
677000, Yakutsk, Ojunsky street 27
I. I. Mulina
Republican hospital №1 «National center of medicine»
Russian Federation
Russian Federation
Mulina Inna Ivanovna – leading visiting hematologist of Ministry of Healthcare of Republic of Sakha (Yakutia), head of department of hematology
677019, Yakutsk, Sergelyakhskoe shosse 4
A. N. Sannikova
National center of medicine
Russian Federation
Russian Federation
Sannikova Anna Nikolaevna – hematologist, head of department of hematology
677019, Yakutsk, Sergelyakhskoe shosse 4
A. M. Palshina
M.K. Ammosov North-Eastern federal university, Institute of medicine
Russian Federation
Russian Federation
Palshina Aida Mikhaylovna – candidate for medical sciences
associate professor at the department «Hospital therapy, occupational diseases and clinical pharmacology»
677000, Yakutsk, Ojunsky street 27
S. S. Sleptsova
M.K. Ammosov North-Eastern federal university, Institute of medicine
Russian Federation
Russian Federation
Sleptsova Snezhana Spiridonovna – doctor for medical sciences, professor, leading visiting infectiologist of Ministry of Healthcare of Republic of Sakha (Yakutia)
deputy director of science
677000, Yakutsk, Ojunsky street 27
Н. Краснова
МИ СВФУ
Russian Federation
Russian Federation
T. N. Aleksandrova
M.K. Ammosov North-Eastern federal university, Institute of medicine
Russian Federation
Russian Federation
Aleksandrova Tuiara Nikonovna – postgraduate student
department «Internal diseases and general medicine»
677000, Yakutsk, Ojunsky street 27
References
1. Five-year results of imatinib (gleevec) in patients with chronic myeloid leukemia in chronic phase / E.Y. Kusnetsova, T.I. Ol’khovik, A.V. Shulmin [et al.] // Fundamental researches. – 2011. - №10. – Р.95-98.
2. Experience of tyrosine kinase inhibitors using in patients with chronic myeloid leukemia in Samara region / I.L. Davydkin, I.I. Syrotko, G.A. Egorova [et al.] // Effektivnaya farmakoterapiya. – 2013. - №4, Vol.46 – Р.14-19.
3. Assessment of adverse drug effects of targeted therapy in patients with chronic myeloid leukemia / M.I.Savelyeva, O.S. Samoylova, I.N. Samarina [et al.] // The Kremlin medicine. Clinical bulletin. – 2012. – №2. – Р.52-55.
4. Russian register for treatment of chronic myeloid leukemia in routine clinical practice: outcome of long-term work//A.G. Turkina, A.K. Golenkov, L.I. Napso [et al.] // Effective pharmacotherapy. – 2015. - №10. – Р.8-13.
5. Federal clinical recommendations for diagnosis and treatment of chronic myeloid leukemia / K.M. Abdulkadyrov, A.O. Abdullaev, L.B. Avdeeva [et al.] // Vestnik gematologii. – 2013. - №3, V.9. – P.4-43.
6. Shukhov O.A. Molecular and cytogenetic characteristic of Ph-positive clone in patients with chronic myeloid leukemia under a long exposure of tirosyne kinase inhibitors: diss. cand. of med. sciences: 14.01.21. / O.A. Shukhov. – M., 2015. – P.113.
7. Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia / S.G. O’Brien, F. Guilhot, R. Larson R [et al.] // N Engl J Med. – 2003. – Vol. 348. – P.994-1004.
Review
For citations:
Yadrikhinskaya V.N., Mulina I.I., Sannikova A.N., Palshina A.M., Sleptsova S.S., , Aleksandrova T.N. Assessment of efficacy of tyrosine kinase inhibitors in treatment of chronic myeloid leukemia. Yakut Medical Journal. 2016;(4):28-31.
Views:
20
Email this article 